Trial Profile
Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID 2019 infections; Hypoxia
- Focus Adverse reactions
- Acronyms PreToVid
- 23 Jun 2021 This trial has been completed in Netherlans, according to European Clinical Trials Database record.
- 05 Jul 2020 Planned End Date changed from 3 Apr 2021 to 3 Jul 2021.
- 24 Apr 2020 New trial record